ArticleEuropean journal of medical research2025
Cardiovascular disease mortality risk among patients with metastatic melanoma before and after the approval of immunotherapy in the United States: a Surveillance, Epidemiology, and End Results database-based study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTo date, the population-based cardiovascular mortality (CVM) of metastatic melanoma has not been studied in the era of immune checkpoint inhibitors (ICIs). This study aims to assess the risk of CVM in patients with metastatic melanoma in the pre-ICI (2000-2010) and post-ICI (2011-2020) eras.
methodsThis study using the Surveillance, Epidemiology, and End Results database from 2000 to 2020 of patients with metastatic melanoma. Standardized mortality ratios (SMRs) and absolute excess risks were calculated for CVM before and after the introduction of ICIs. To evaluate the cumulative mortality (CM) rate for all causes of death, cumulative hazard curves were constructed. Competing risk models were established to determine the independent predictors for CVM.
resultsThis study included 8857 patients, 3803 in the pre-ICI era and 5054 in the post-ICI era. A total of 281 deaths were attributed to cardiovascular diseases. The overall SMRs of CVM were 27% higher (SMR = 1.27, 95% CI 1.06-1.50) in the pre-ICI era and 56% higher (SMR = 1.56, 95% CI 1.31-1.83) in the post-ICI era than the general population, reaching 2.17 during the early stage of latency (0-5 months). Additionally, independent risk factors for CVM included age, primary site, and brain metastases in the post-ICI era.
conclusionsMetastatic melanoma patients exhibited an elevated CVM risk after the approval of ICIs, peaking in early latency period and older population. Timely monitoring and effective interventions for cardiovascular diseases may be warranted in patients with metastatic melanoma, especially in the immunotherapy era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.